TherapeuticsMD Statistics
Share Statistics
TherapeuticsMD has 11.53M shares outstanding. The number of shares has increased by 9.05% in one year.
| Shares Outstanding | 11.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.34M |
| Failed to Deliver (FTD) Shares | 875 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 21.27K, so 0.18% of the outstanding shares have been sold short.
| Short Interest | 21.27K |
| Short % of Shares Out | 0.18% |
| Short % of Float | 0.19% |
| Short Ratio (days to cover) | 0.99 |
Valuation Ratios
The PE ratio is -3.04 and the forward PE ratio is 4.29.
| PE Ratio | -3.04 |
| Forward PE | 4.29 |
| PS Ratio | 24 |
| Forward PS | 1.2 |
| PB Ratio | 1.07 |
| P/FCF Ratio | -0.65 |
| PEG Ratio | n/a |
Enterprise Valuation
TherapeuticsMD Inc. has an Enterprise Value (EV) of 27.17M.
| EV / Earnings | -2.64 |
| EV / Sales | 20.87 |
| EV / EBITDA | -3.23 |
| EV / EBIT | -3.19 |
| EV / FCF | -0.56 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.
| Current Ratio | 1.72 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.35% and return on capital (ROIC) is -22.73%.
| Return on Equity (ROE) | -0.35% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -22.73% |
| Revenue Per Employee | 1.30M |
| Profits Per Employee | -10.28M |
| Employee Count | 1 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -43.00K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -56.14% in the last 52 weeks. The beta is 1.14, so TherapeuticsMD 's price volatility has been higher than the market average.
| Beta | 1.14 |
| 52-Week Price Change | -56.14% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 1.7 |
| Relative Strength Index (RSI) | 40.83 |
| Average Volume (20 Days) | 293.23K |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of 1.30M and earned -10.28M in profits. Earnings per share was -0.55.
| Revenue | 1.30M |
| Gross Profit | 1.30M |
| Operating Income | -8.52M |
| Net Income | -10.28M |
| EBITDA | -8.40M |
| EBIT | -8.52M |
| Earnings Per Share (EPS) | -0.55 |
Balance Sheet
The company has 4.33M in cash and 8.01M in debt, giving a net cash position of -3.68M.
| Cash & Cash Equivalents | 4.33M |
| Total Debt | 8.01M |
| Net Cash | -3.68M |
| Retained Earnings | -949.64M |
| Total Assets | 39.55M |
| Working Capital | 6.18M |
Cash Flow
In the last 12 months, operating cash flow was -48.14M and capital expenditures 0, giving a free cash flow of -48.14M.
| Operating Cash Flow | -48.14M |
| Capital Expenditures | 0 |
| Free Cash Flow | -48.14M |
| FCF Per Share | -3.47 |
Margins
Gross margin is 100%, with operating and profit margins of -654.61% and -789.4%.
| Gross Margin | 100% |
| Operating Margin | -654.61% |
| Pretax Margin | -594.62% |
| Profit Margin | -789.4% |
| EBITDA Margin | -645.24% |
| EBIT Margin | -654.61% |
| FCF Margin | -3.70K% |
Dividends & Yields
TXMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -55% |
| FCF Yield | -418.66% |
Analyst Forecast
Currently there are no analyst rating for TXMD.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 9, 2022. It was a backward split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -33.1 |
| Piotroski F-Score | 2 |